(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -19.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 283.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.14%.
Metagenomi's revenue in 2025 is $33,768,000.On average, 5 Wall Street analysts forecast MGX's revenue for 2025 to be $1,035,276,490, with the lowest MGX revenue forecast at $647,371,530, and the highest MGX revenue forecast at $1,286,335,637. On average, 5 Wall Street analysts forecast MGX's revenue for 2026 to be $949,625,874, with the lowest MGX revenue forecast at $367,824,733, and the highest MGX revenue forecast at $1,576,391,712.
In 2027, MGX is forecast to generate $379,084,674 in revenue, with the lowest revenue forecast at $367,824,733 and the highest revenue forecast at $394,097,928.